In a completed phase III clinical trial (NCT00002544) and a recruiting clinical trial (NCT04927481), mitoxantrone hydrochloride has been tested on women with metastatic BC and patients with advanced HER2-negative BC, respectively. Here, ERBB2 is linked to breast cancer.